Remove Assay Development Remove Pharmacokinetics Remove Research
article thumbnail

Meet the Researcher: Dennis Brown, Kintara Therapeutics 

Drug Discovery World

At the American Association of Cancer Research’s Annual Meeting in Orlando, Florida, DDW’s Megan Thomas met with industry experts to learn more about their research and careers in the field of cancer research. In this sector, everything sounds very regimented, but there is a lot of serendipity in how things develop.

Research 130
article thumbnail

Choosing the Best Bioanalytical Platform for Your Program

Alta Sciences

Our solutions include standalone services or integrated programs, providing assay development and top-quality data for toxicokinetic (TK) , pharmacokinetic (PK), and pharmacodynamic (PD) determinations to support your nonclinical and clinical studies. Why Partner With Altasciences for Your Bioanalytical Projects?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Reflecting on ELRIG’s Drug Discovery 2022 

Drug Discovery World

Meanwhile, Stratech Bio were on hand to answer enquiries about their range of raw materials, kits and assays for R&D or bioprocessing projects. Over at LabLogic, product specialists were on hand to share expertise and solutions, and gave a brief talk in Auditorium 1 to give an overview of the LabLogic products. Looking forward .

Drugs 130
article thumbnail

The evolution of assays for immuno-oncology research

Drug Discovery World

The first such research dates back to 1891, when William Coley attempted to inject heat-inactivated bacteria to treat osteosarcoma. Rising demand The global immuno-oncology assay market is expected to grow at a compound annual growth rate (CAGR) of 11.87% from 2021 to 2030 to reach 11.74bn USD by 2030 7.

Research 130
article thumbnail

Article EMA Thank You EMA finalizes clinical anticancer therapeutic guidance update

Agency IQ

The European Commission also implemented its Mission on Cancer , which aims to further cancer research and innovation through funding in the same areas as the cancer plan. The EMA started providing guidance on the clinical development of anticancer therapeutics in 1996.